Hello, Sorrento Fam!

It appears that another NDA was filed in China back in May of 2023 for our A166, Anti-HER2 ADC through Kelun Biotech (we have a partnership with Kelun through our subsidiary, Levena Biopharma).

https://www.biospace.com/article/releases/sichuan-kelun-biotech-biopharmaceutical-co-ltd-and-levena-biopharma-are-to-present-positive-clinical-progress-of-a166-an-anti-her2-adc-in-treating-locally-advanced-or-metastatic-her2-positive-breast-cancer-patients-at-the-asco-2022/

https://www.prnewswire.com/apac/news-releases/kelun-biotech-announces-interim-results-for-2023-global-strategic-partnership-and-rich-pipeline-boost-significant-revenue-growth-in-the-first-half-of-the-year-301911333.html

Please continue to share this petition so that we can continue to garner more attention to our case and to related updates!

We’re making progress!

Look at Law Prof. Nancy Rapoport’s article below.  She has taken notice of our case!!

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4700214

GLTAL!
Kimberly